Neurometrix Completes Merger and Delists from Nasdaq

Neurometrix ( (NURO) ) has shared an announcement.

Neurometrix has undergone a significant corporate restructuring through a merger agreement, resulting in the cancellation and conversion of its common and preferred stock into cash and contingent value rights (CVRs). The merger, effective as of May 2, 2025, also led to the delisting of its common stock from Nasdaq and changes in its board and executive leadership, with new directors and executives appointed from the merger partner’s team.

Spark’s Take on NURO Stock

According to Spark, TipRanks’ AI Analyst, NURO is a Neutral.

Neurometrix’s overall stock score is primarily impacted by its weak financial performance marked by declining revenues and persistent losses. While technical indicators show some positive momentum, the stock’s unattractive valuation, due to its negative earnings and lack of dividends, further drags down the score. Improvement in financial health and sustainable profitability are essential for a better outlook.

To see Spark’s full report on NURO stock, click here.

More about Neurometrix

YTD Price Performance: 16.54%

Average Trading Volume: 6,566

Technical Sentiment Signal: Buy

Current Market Cap: $9.43M

For detailed information about NURO stock, go to TipRanks’ Stock Analysis page.